Kitov Announces U.S. FDA Acceptance of Investigational New Drug Application to Conduct Phase 1/2 Clinical Trial of NT219 in Multiple Types of Advanced Cancer Patients
22 mai 2020 07h00 HE
|
Kitov Pharma Ltd.
Company to Evaluate NT219 as Monotherapy Treatment of Advanced Solid Tumors and in Combination with Cetuximab for Treatment of Recurrent or Metastatic Solid Tumors and Head and Neck Cancer in a Phase...
Kitov Announces U.S. Commercial Launch of Consensi™
20 mai 2020 07h30 HE
|
Kitov Pharma Ltd.
TEL AVIV, Israel, May 20, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...
Kitov to Present Preclinical Data on NT219 at American Association of Cancer Research Virtual Annual Meeting II
19 mai 2020 08h05 HE
|
Kitov Pharma Ltd.
Company Expects to Initiate Phase 1/2 Trial of NT-219 as Monotherapy Treatment of Advanced Solid Tumors and in Combination with cetuximab for Treatment of Recurrent or Metastatic Solid Tumors and Head...
Kitov to Present Phase 1 Data on CM-24 in Patients with Advanced Cancer at American Society of Clinical Oncology 2020 Virtual Scientific Program
14 mai 2020 07h10 HE
|
Kitov Pharma Ltd.
Company Expects to Initiate Phase 1/2 Clinical trial, in Collaboration with Bristol Myers Squibb, with CM-24 in Combination with nivolumab (Opdivo®) in Second Half of 2020 TEL AVIV, Israel, May...
Kitov Closes $10 Million Registered Direct Offering
08 mai 2020 16h00 HE
|
Kitov Pharma Ltd.
TEL-AVIV, Israel, May 08, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...
Kitov Announces $10 million Registered Direct Offering
06 mai 2020 08h00 HE
|
Kitov Pharma Ltd.
TEL-AVIV, Israel, May 06, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...
Kitov Pharma Ltd. Announces Cash Proceeds of $6.5 Million from Exercise of Warrants
20 avr. 2020 08h05 HE
|
Kitov Pharma Ltd.
TEL-AVIV, Israel, April 20, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion...
Kitov Closes $6.0 Million Public Offering
17 mars 2020 08h00 HE
|
Kitov Pharma Ltd.
TEL-AVIV, March 17, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug...
Kitov Pharma Provides Update on Planned U.S. Launch of Consensi™ and Provides Three-Year Revenue Forecast
12 mars 2020 08h15 HE
|
Kitov Pharma Ltd.
Company’s marketing partners in the U.S. plan to commence selling Consensi in May 2020Kitov expects to receive between $28 million and $36 million in milestone and royalty revenues from 2020 through...
Kitov Announces Pricing of $6.0 Million Public Offering
12 mars 2020 08h00 HE
|
Kitov Pharma Ltd.
TEL-AVIV, Israel, March 12, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...